TY - JOUR
T1 - Recognition and management of persistent chylomicronemia
T2 - A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology
AU - Saadatagah, Seyedmohammad
AU - Larouche, Miriam
AU - Naderian, Mohammadreza
AU - Nambi, Vijay
AU - Brisson, Diane
AU - Kullo, Iftikhar J.
AU - Duell, P. Barton
AU - Michos, Erin D.
AU - Shapiro, Michael D.
AU - Watts, Gerald F.
AU - Gaudet, Daniel
AU - Ballantyne, Christie M.
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025/6
Y1 - 2025/6
N2 - Extreme hypertriglyceridemia, defined as triglyceride (TG) levels ≥1000 mg/dL, is almost always indicative of chylomicronemia. The current diagnostic approach categorizes individuals with chylomicronemia into familial chylomicronemia syndrome (FCS; prevalence 1–10 per million), caused by the biallelic combination of pathogenic variants that impair the lipolytic action of lipoprotein lipase (LPL), or multifactorial chylomicronemia syndrome (MCS, 1 in 500). A pragmatic framework should emphasize the severity of the phenotype and the risk of complications. Therefore, we endorse the term “persistent chylomicronemia” defined as TG ≥1000 mg/dL in more than half of the measurements to encompass patients with the highest risk for pancreatitis, regardless of their genetic predisposition. We suggest classification of PC into four subtypes: 1) genetic FCS, 2) clinical FCS, 3) PC with “alarm” features, and 4) PC without alarm features. Although patients with FCS most likely have PC, the vast majority with PC do not have genetic FCS. Proposed alarm features are: (a) history of recurrent TG-induced acute pancreatitis, (b) recurrent hospitalizations for severe abdominal pain without another identified cause, (c) childhood pancreatitis, (d) family history of TG-induced pancreatitis, and/or (e) post-heparin LPL activity <20 % of normal value. Alarm features constitute the strongest risk factors for future acute pancreatitis risk. Patients with PC and alarm features have very high risk of pancreatitis, comparable to that in patients with FCS. Effective, innovative treatments for PC, like apoC-III inhibitors, have been developed. Combined with lifestyle modifications, these agents markedly lower TG levels and risk of pancreatitis in the very-high-risk groups, irrespective of the monogenic etiology. Pragmatic definitions, education, and focus on patients with PC specifically those with alarm features could help mitigate the risk of acute pancreatitis and other complications.
AB - Extreme hypertriglyceridemia, defined as triglyceride (TG) levels ≥1000 mg/dL, is almost always indicative of chylomicronemia. The current diagnostic approach categorizes individuals with chylomicronemia into familial chylomicronemia syndrome (FCS; prevalence 1–10 per million), caused by the biallelic combination of pathogenic variants that impair the lipolytic action of lipoprotein lipase (LPL), or multifactorial chylomicronemia syndrome (MCS, 1 in 500). A pragmatic framework should emphasize the severity of the phenotype and the risk of complications. Therefore, we endorse the term “persistent chylomicronemia” defined as TG ≥1000 mg/dL in more than half of the measurements to encompass patients with the highest risk for pancreatitis, regardless of their genetic predisposition. We suggest classification of PC into four subtypes: 1) genetic FCS, 2) clinical FCS, 3) PC with “alarm” features, and 4) PC without alarm features. Although patients with FCS most likely have PC, the vast majority with PC do not have genetic FCS. Proposed alarm features are: (a) history of recurrent TG-induced acute pancreatitis, (b) recurrent hospitalizations for severe abdominal pain without another identified cause, (c) childhood pancreatitis, (d) family history of TG-induced pancreatitis, and/or (e) post-heparin LPL activity <20 % of normal value. Alarm features constitute the strongest risk factors for future acute pancreatitis risk. Patients with PC and alarm features have very high risk of pancreatitis, comparable to that in patients with FCS. Effective, innovative treatments for PC, like apoC-III inhibitors, have been developed. Combined with lifestyle modifications, these agents markedly lower TG levels and risk of pancreatitis in the very-high-risk groups, irrespective of the monogenic etiology. Pragmatic definitions, education, and focus on patients with PC specifically those with alarm features could help mitigate the risk of acute pancreatitis and other complications.
KW - Chylomicronemia
KW - Familial chylomicronemia syndrome
KW - Hypertriglyceridemia
KW - Multifactorial chylomicronemia syndrome
KW - Pancreatitis
KW - Persistent chylomicronemia
KW - apoC-III inhibitors
UR - http://www.scopus.com/inward/record.url?scp=105001867445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105001867445&partnerID=8YFLogxK
U2 - 10.1016/j.ajpc.2025.100978
DO - 10.1016/j.ajpc.2025.100978
M3 - Article
AN - SCOPUS:105001867445
SN - 2666-6677
VL - 22
JO - American Journal of Preventive Cardiology
JF - American Journal of Preventive Cardiology
M1 - 100978
ER -